

# **Bempedoic Acid-Associated Tendinopathy and the Frontier of Tendon Repair: An Integrative Analysis of Pharmacological Risk and Novel Therapeutic Strategies**

## **Introduction**

In the clinical management of atherosclerotic cardiovascular disease (ASCVD), the reduction of low-density lipoprotein cholesterol (LDL-C) remains a cornerstone of preventive cardiology.<sup>1</sup> While statins are the undisputed first-line therapy, their utility is frequently limited by statin-associated muscle symptoms (SAMS), which can lead to non-adherence or discontinuation in a significant subset of patients.<sup>2</sup> This therapeutic gap has spurred the development of alternative lipid-lowering agents. Among these, bempedoic acid has emerged as a novel, mechanistically distinct oral therapy that effectively lowers LDL-C without the high incidence of myalgia associated with statins.<sup>4</sup>

However, the clinical deployment of bempedoic acid has been accompanied by a safety signal of concern: an observed association with tendon damage and rupture.<sup>7</sup> This adverse event, while infrequent, is poorly understood and has been included as a warning in the drug's prescribing information. For patients and clinicians navigating the complex risk-benefit landscape of long-term preventive medicine, this uncertainty presents a significant challenge. The proactive health investigator, seeking to optimize cardiovascular health while minimizing iatrogenic harm, is therefore confronted with a series of critical questions. What is the true magnitude of this risk? What are the underlying biological mechanisms? And, most pragmatically, what can be done to mitigate or treat this specific form of drug-induced injury?

This report provides an exhaustive, expert-level analysis designed to address these questions. It begins by meticulously dissecting the pharmacological profile of bempedoic acid and the clinical evidence for its association with tendinopathy, highlighting a conspicuous and critical gap in our understanding of its mechanism. Finding no specific therapies for bempedoic acid-induced tendon injury, the report

then broadens its scope to provide a comprehensive framework for management based on general principles of tendinopathy treatment. Subsequently, it transitions to a critical review of the entire landscape of adjunctive and alternative therapies for tendon health, systematically evaluating the evidence for nutraceuticals, botanicals, and cutting-edge experimental agents. This integrative analysis synthesizes clinical trial data, preclinical mechanistic studies, and non-scholarly patient experiences to deliver a nuanced and actionable understanding of the risks of bempedoic acid and the vast, evolving frontier of tendon repair.

## **Part I: Bempedoic Acid and Tendinopathy — An Evidence-Based Assessment**

This section deconstructs the documented association between bempedoic acid and tendon injury. It begins with the drug's fundamental pharmacology, which is essential for understanding its potential off-target effects, before moving to a critical analysis of the clinical trial data and the significant lack of a proven causal mechanism.

### **Section 1.1: Pharmacological and Mechanistic Profile of Bempedoic Acid**

A foundational understanding of bempedoic acid's mechanism of action is crucial for contextualizing its safety profile, particularly in relation to tendon tissue. Bempedoic acid is administered as an oral prodrug, meaning it is biologically inactive until it undergoes metabolic conversion.<sup>4</sup> This activation occurs via the enzyme very long-chain acyl-CoA synthetase-1 (ACSVL1), which converts bempedoic acid into its active form, bempedoyl-CoA.<sup>9</sup>

The key to bempedoic acid's favorable muscle safety profile lies in its tissue-specific activation. The ACSVL1 enzyme is expressed robustly in the liver and, to a lesser extent, the kidneys, but it is notably absent in skeletal muscle.<sup>3</sup> This liver-centric activation prevents the drug from exerting its primary effect within muscle cells, thereby circumventing the mechanism thought to contribute to statin-associated muscle symptoms.<sup>4</sup>

Once activated in the liver, bempedoyl-CoA inhibits the enzyme ATP-citrate lyase (ACLY).<sup>2</sup> ACLY is a key enzyme in the cholesterol biosynthesis pathway, acting two steps upstream of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the enzyme targeted by statins.<sup>9</sup> By inhibiting ACLY, bempedoic acid reduces the pool of acetyl-CoA available for cholesterol synthesis. This reduction in hepatic cholesterol leads to a compensatory upregulation of LDL receptors on the surface of liver cells, which in turn enhances the clearance of LDL-C from the bloodstream.<sup>4</sup>

Beyond its primary mechanism, bempedoic acid has a well-characterized off-target effect on uric acid metabolism. It is known to cause mild elevations in serum uric acid and can increase the risk of gout in susceptible individuals.<sup>5</sup> This effect is not related to ACLY inhibition but is instead caused by competition between a metabolite of bempedoic acid (bempedoic acid glucuronide) and uric acid for the same organic anion transporter 2 (OAT2) in the renal tubules.<sup>5</sup> This competition modestly reduces the renal excretion of uric acid, leading to its accumulation in the blood. The existence of this well-elucidated, non-primary mechanism stands in stark contrast to the complete absence of a known mechanism for its effects on tendon tissue.

## **Section 1.2: The Clinical Evidence for Tendon-Related Adverse Events**

The evidence linking bempedoic acid to tendon injury has evolved over time, originating from smaller early trials and becoming more nuanced with the release of data from a large-scale cardiovascular outcomes study. The initial warning included in the U.S. Prescribing Information (USPI) was based on pooled data from two 52-week, placebo-controlled trials that included a total of 3,621 patients.<sup>8</sup> In these foundational studies, tendon rupture was observed in 0.5% of patients receiving bempedoic acid, compared to 0% of patients receiving placebo.<sup>8</sup> The ruptures were not confined to a single location, affecting the rotator cuff, biceps tendon, and Achilles tendon, and typically manifested within weeks to months of initiating therapy.<sup>7</sup>

This initial signal prompted the identification of several risk factors that appear to predispose patients to this adverse event. These include being over 60 years of age, concomitant use of corticosteroids or fluoroquinolone antibiotics, the presence of renal failure, and a prior history of tendon disorders.<sup>7</sup>

However, the definitive evidence on bempedoic acid's safety and efficacy comes from the landmark CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting

Regimen) Outcomes trial.<sup>8</sup> This much larger and longer study randomized 13,970 statin-intolerant patients to either bempedoic acid or placebo and followed them for a median of 3.4 years.<sup>14</sup> The results provided a more refined, and arguably less alarming, picture of the tendon-related risk. In the CLEAR trial, adjudicated events of tendon rupture occurred in 1.2% of patients in the bempedoic acid group versus 0.9% in the placebo group.<sup>14</sup> Furthermore, when considering the broader category of all tendon-related troubles (TRT), which includes both tendinopathies and ruptures, the incidence was identical in both arms of the study, at 2.0%.<sup>14</sup>

The evolution of this safety signal from an absolute difference in early trials (0.5% vs. 0%) to a small, non-statistically significant numerical difference in the definitive outcomes trial (1.2% vs. 0.9%) is a critical point of analysis. Regulatory bodies often act cautiously on early signals, especially when a "zero-event" comparator is present, making the initial warning understandable. However, the large-scale, long-term data from CLEAR Outcomes provide a more reliable estimate of the true risk. The absolute risk difference of only 0.3% for rupture, coupled with an identical overall rate of tendon issues, suggests that the risk attributable to the drug itself is likely very small and may be significantly confounded by the high prevalence of underlying risk factors in this patient population. This interpretation is supported by commentary from lead investigators like Dr. Steven Nissen, who publicly stated he felt the initial data were "very weak" and questioned whether the effect would be confirmed in the larger trial.<sup>6</sup> Indeed, subsequent clinical discussions have noted that the concern around tendon pathology was "not detected" in the CLEAR Outcomes trial, reflecting the dilution of the initial signal.<sup>18</sup>

**Table 1: Summary of Clinical Trial Data on Bempedoic Acid and Tendon-Related Adverse Events**

Trial/Study	Patient Population	Follow-up	Tendon Rupture (Bempedoic Acid)	Tendon Rupture (Placebo)	Overall TRT* (Bempedoic Acid)	Overall TRT* (Placebo)	Source(s)
Pooled Phase 3 Trials	2,425 (BA) vs. 1,196 (Placebo)	52 weeks	0.5%	0%	Not Reported	Not Reported	<sup>8</sup>
CLEAR	6,992	Median	1.2%	0.9%	2.0%	2.0%	<sup>14</sup>

Outcomes Trial	(BA) vs. 6,978 (Placebo)	3.4 years					
----------------	--------------------------	-----------	--	--	--	--	--

\*TRT: Tendon Rupture and Tendinopathies

**Section 1.3: The Unexplained Link: A Critical Evaluation of Proposed Mechanisms**

Perhaps the most striking aspect of the association between bempedoic acid and tendinopathy is the complete absence of a scientifically proposed or validated biological mechanism.<sup>9</sup> The extensive body of scholarly literature details its primary cholesterol-lowering action and the renal transporter competition causing hyperuricemia with precision, yet it remains silent on how the drug might interact with tendon tissue.<sup>5</sup> This "mechanism gap" is a profound area of uncertainty.

The central unanswered question revolves around the activating enzyme, ACSVL1. Bempedoic acid's safety in muscle is predicated on the absence of ACSVL1 in that tissue. However, the available research does not specify whether ACSVL1 is expressed in human tenocytes (the primary cells of tendons) or the surrounding tendon sheath. If ACSVL1 is not present in tendon tissue, it is difficult to conceive of a direct pharmacological mechanism, as the prodrug would not be converted to its active, ACLY-inhibiting form locally. If ACSVL1 is present, then a direct effect becomes plausible, but this has not been investigated.

To contextualize this knowledge deficit, it is useful to compare bempedoic acid with other drugs known for tenotoxicity, such as fluoroquinolone antibiotics. The mechanisms underlying fluoroquinolone-induced tendinopathy, while complex and not fully elucidated, are the subject of extensive research. Proposed mechanisms include direct cytotoxicity to tenocytes, the generation of intracellular reactive oxygen species (ROS) leading to oxidative stress, chelation of magnesium ions which disrupts the crucial interaction between cells and the extracellular matrix (ECM), and the upregulation of matrix metalloproteinases (MMPs)—enzymes that degrade collagen and other ECM components.<sup>20</sup> The existence of these multiple, well-researched hypotheses for fluoroquinolones throws the mechanistic vacuum surrounding bempedoic acid into sharp relief.

**Table 2: Mechanistic Comparison of Drug-Induced Tendinopathies**

Proposed Mechanism	Bempedoic Acid	Statins	Fluoroquinolones
Local Activation in Tendon	Unknown (ACSVL1 expression not studied)	Not Applicable	Not Applicable
Direct Cytotoxicity	Not Proposed	Proposed (inhibition of tenocyte repair/regeneration) <sup>25</sup>	Proposed <sup>22</sup>
Oxidative Stress (ROS)	Not Proposed	Not Proposed	Proposed <sup>23</sup>
MMP Upregulation	Not Proposed	Not Proposed	Proposed <sup>20</sup>
Cell-Matrix Disruption	Not Proposed	Not Proposed	Proposed (via ion chelation) <sup>22</sup>
Cholesterol Synthesis Inhibition	Not Proposed (as a tendon-specific mechanism)	Proposed (may impair cell membrane integrity)	Not Applicable

## Part II: Management and Therapeutic Strategies for Drug-Induced Tendon Injury

This part addresses the practical question of how to manage tendon damage should it arise in a patient taking bempedoic acid. It first establishes the lack of specific treatments before outlining a logical management framework based on established principles for other forms of tendinopathy.

### Section 2.1: Current Clinical Guidance and an Unmet Therapeutic Need

A comprehensive search of the scientific and clinical literature reveals a critical

negative finding: there are no published studies, case reports, or clinical trials that specifically investigate the reversal or treatment of tendon damage caused by bempedoic acid.<sup>8</sup> This lack of targeted research is likely a direct consequence of the very low and uncertain risk profile established in Part I. With a small absolute risk increase and no clear biological mechanism, there is little clinical or commercial impetus to develop a specific antidote or reversal agent.

Consequently, the current clinical guidance is straightforward and preventative in nature. The manufacturer, along with regulatory bodies, recommends the immediate discontinuation of bempedoic acid at the first sign of tendon rupture or injury, such as pain, swelling, or inflammation in a tendon area.<sup>7</sup> Furthermore, the medication should be avoided altogether in patients who have a known history of tendon disorders or who possess multiple risk factors for tendinopathy.<sup>8</sup> This leaves a significant unmet therapeutic need for patients who may experience this adverse event and are seeking strategies beyond simple cessation of the drug.

## **Section 2.2: A Framework for Management Based on General Tendinopathy Principles**

In the absence of specific treatment protocols for bempedoic acid-induced tendinopathy, a logical management framework must be extrapolated from the established principles used to treat general and other drug-induced tendon injuries. This approach is grounded in reducing acute stress and then progressively stimulating the body's natural repair processes.

The first and most critical step is the immediate discontinuation of the suspected causative agent, bempedoic acid.<sup>22</sup> This removes the ongoing chemical insult, which is a prerequisite for healing. The initial management of acute symptoms should follow the conventional RICE (Rest, Ice, Compression, Elevation) protocol. Rest involves avoiding activities that stress the injured tendon, while ice can be applied for up to 20 minutes several times a day to help manage pain and swelling.<sup>28</sup> Short-term use of oral non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen can also be effective for relieving acute pain.<sup>28</sup>

For rehabilitation, a phased approach, similar to that recommended for fluoroquinolone-induced tendinopathy, is appropriate.<sup>20</sup> The initial phase focuses on protecting the tendon and reducing stress to allow the tissue to recover from the

chemical injury. This may involve the use of crutches for lower limb injuries or orthotic devices to immobilize the affected area.<sup>30</sup> Once the acute phase has subsided, a second phase of progressive loading should be initiated under the guidance of a physical therapist. This involves a structured program of exercises, such as eccentric loading or heavy slow resistance training, designed to stimulate fibroblast activity and promote the synthesis and remodeling of the collagen matrix, thereby improving the tendon's structural integrity and mechanical strength.<sup>28</sup>

Throughout the management process, it is crucial to avoid interventions that could further harm the tendon. Of particular note are corticosteroid injections. While they may provide short-term pain relief, repeated injections have been shown to weaken tendon tissue and can increase the long-term risk of complete rupture.<sup>28</sup>

## **Part III: Nutraceutical and Botanical Interventions for Tendon Health: A Review of the Evidence**

Given the lack of specific pharmacological treatments for drug-induced tendinopathy, many patients and clinicians turn to nutraceutical and botanical supplements for support. This section critically evaluates the scientific evidence for these interventions, organizing them by their proposed mechanisms of action.

### **Section 3.1: Overview of Natural Compounds in Tendinopathy Management**

The use of dietary supplements to support tendon health is widespread, but the clinical evidence remains in its early stages. A 2015 systematic review by Maffulli et al. examined several of the most common nutraceuticals, including glucosamine, chondroitin sulfate, vitamin C, hydrolyzed collagen, arginine, bromelain, curcumin, boswellic acid, and methylsulfonylmethane (MSM).<sup>31</sup> The authors concluded that while preclinical data are often very encouraging—showing positive effects on collagen synthesis, inflammation, mechanical properties, and antioxidant status—these findings are not yet fully confirmed by high-quality clinical studies. A major limitation identified in the clinical literature is the common practice of administering these compounds in combination formulas, which makes it impossible to determine the



effect of any single ingredient.<sup>31</sup> A more recent (2022) systematic review and meta-analysis provided further insight, finding that the addition of dietary supplements to a standard physiotherapeutic treatment regimen significantly improved pain reduction, but had no significant effect on functional outcomes.<sup>32</sup>

To better understand this diverse landscape, it is useful to categorize these supplements into a conceptual framework based on their primary proposed mechanism: "Building Blocks" versus "Signaling Modulators."

- **Building Blocks:** These compounds are theorized to work by directly providing the raw materials or essential co-factors needed for the synthesis and repair of the tendon's extracellular matrix (ECM). This category includes substances like hydrolyzed collagen peptides and vitamin C, which is an indispensable co-enzyme in the hydroxylation of proline and lysine, a critical step in collagen formation.<sup>31</sup>
- **Signaling Modulators:** These compounds are thought to exert their effects by modulating key intracellular signaling pathways that control inflammation, cell death (apoptosis), oxidative stress, and regeneration. This category includes polyphenols like curcumin and endogenous fatty acid amides like palmitoylethanolamide (PEA), which can influence complex networks such as the NF-κB and PPAR pathways.<sup>33</sup>

**Table 3: Evidence Summary for Natural Compounds in Tendinopathy Treatment**

Compound	Mechanism Category	Key Molecular Target(s)	Level of Evidence	Summary of Findings	Source(s)
Curcumin	Signaling Modulator	NF-κB, PI3K/Akt, COX-2, Inflammatory Cytokines	Preclinical, Small Human Studies, Systematic Reviews	Potent anti-inflammatory and antioxidant. Promotes tenogenesis in vitro. Reduces pain in some human studies. Bioavailability is a key challenge.	33
Palmitoylet	Signaling	PPAR-α,	Preclinical,	Strong	35

<b>hanolamide (PEA)</b>	Modulator	Mast Cells, GPR55	Multiple RCTs, Meta-Analyses (for pain)	evidence for analgesic and anti-inflammatory effects in chronic pain. Potential cytotoxicity to tendon stem cells at high doses in vitro.	
<b>Specific Collagen Peptides</b>	Building Block	Collagen Precursors (Glycine, Proline)	Preclinical, Pilot Clinical Trials	Provides amino acids for ECM synthesis. Clinically shown to accelerate recovery from Achilles tendinopathy when combined with exercise.	40
<b>Vitamin C</b>	Building Block (Co-factor)	Prolyl/Lysyl Hydroxylase	Established Biochemistry , Preclinical	Essential co-factor for collagen synthesis. Deficiency impairs procollagen formation. Often included in combination supplements .	31
<b>Vitamin D</b>	Signaling Modulator	Vitamin D Receptor (VDR)	Preclinical	VDR activation in tenocytes increases	33

				Type I collagen mRNA and decreases MMPs. Deficiency may be a limiting factor in repair.	
<b>Boswellic Acid</b>	Signaling Modulator	5-LOX	Preclinical, Few Clinical	Anti-inflammatory effects. Evidence for tendon disorders is limited and often from combination products.	31

### Section 3.2: Curcumin: A Multi-Targeted Anti-Inflammatory and Pro-Tenogenic Agent

Curcumin, the primary bioactive compound in turmeric, is a polyphenol that has been extensively studied for its pleiotropic effects. Its potential benefit in tendinopathy stems from its demonstrated antialgic, antioxidant, and potent anti-inflammatory properties.<sup>33</sup> Mechanistically, curcumin modulates a vast array of cellular signaling pathways. It is a well-established inhibitor of nuclear factor kappa B (NF-κB), a master transcription factor that orchestrates the expression of numerous pro-inflammatory genes, including cytokines and enzymes like COX-2.<sup>34</sup>

Preclinical evidence for curcumin's role in tendon healing is robust. *In vitro* studies using human tenocytes have shown that curcumin can protect cells from the degenerative effects of inflammatory cytokines like interleukin-1β (IL-1β). It does so by preserving the synthesis of essential ECM proteins, including collagen type I and III, and by inhibiting the cytokine-induced activation of NF-κB via the PI3K/Akt signaling pathway.<sup>37</sup> Animal models of tendon injury further support these findings, demonstrating that curcumin treatment can lead to better organization of newly

formed collagen fibers, improved biomechanical strength of the repaired tendon, and reduced markers of oxidative stress.<sup>33</sup> Most recently, research has suggested that curcumin may improve functional recovery not just by mitigating inflammation, but by actively promoting tenogenesis—the differentiation of tendon stem cells into mature tendon cells.<sup>36</sup>

Despite this promising preclinical data, the human clinical evidence is less definitive. Some studies suggest that curcumin supplementation, when used as an adjunct to conventional treatment, can improve pain scores in patients with tendinopathy.<sup>33</sup> However, a major challenge with curcumin is its poor oral bioavailability; only a small fraction of ingested curcumin is absorbed into the bloodstream.<sup>44</sup> Experts recommend using supplement formulations designed to enhance absorption, such as those containing piperine (black pepper extract) or those formulated with phospholipids or nanoparticles.<sup>44</sup> Anecdotal reports from consumers on commercial platforms often praise curcumin's effectiveness for general inflammatory conditions like sciatica, costochondritis, and post-exercise soreness, lending some support to its anti-inflammatory and analgesic reputation, although specific mentions of tendinopathy are less frequent.<sup>45</sup>

### **Section 3.3: Palmitoylethanolamide (PEA): An Endocannabinoid-like Modulator with a Complex Profile**

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that the body produces on demand in response to injury and inflammation.<sup>35</sup> As a supplement, it has gained significant attention for its analgesic and anti-inflammatory effects, which are mediated through mechanisms distinct from those of NSAIDs.<sup>48</sup> PEA's primary molecular target is the peroxisome proliferator-activated receptor alpha (PPAR- $\alpha$ ), a nuclear receptor that regulates genes involved in lipid metabolism and inflammation.<sup>35</sup> Additionally, it exerts a powerful local anti-inflammatory effect by stabilizing mast cells and preventing their degranulation, a mechanism termed Autacoid Local Inflammation Antagonism (ALIA).<sup>35</sup> PEA also interacts indirectly with the endocannabinoid system, inhibiting the breakdown of the endocannabinoid anandamide, thereby enhancing its effects in what is known as the "entourage effect".<sup>35</sup>

The clinical evidence supporting PEA's efficacy as a pain reliever is substantial. Multiple systematic reviews and meta-analyses of randomized controlled trials have concluded that PEA is an effective and well-tolerated treatment for various forms of

chronic pain, including neuropathic and musculoskeletal pain, with a very favorable safety profile and virtually no reported side effects.<sup>39</sup> However, anecdotal reports from patient forums are more mixed; while some users report significant benefits, others find the effects to be inconsistent or to wane over time, highlighting a potential for variable individual responses.<sup>53</sup>

Despite its widespread promotion as a safe anti-inflammatory agent, a crucial *in vitro* study introduces a significant note of caution regarding its use for tendon repair. In a 2020 study by Gissi et al., researchers investigated the cytotoxicity of several common supplements on human tendon-derived stem cells (hTDSCs), the very cells responsible for tendon regeneration.<sup>38</sup> They found that high concentrations of PEA, much like the potent glucocorticoid drug Triamcinolone, significantly reduced the viability of these essential stem cells.<sup>38</sup>

This finding creates a potential paradox: a compound taken to reduce inflammation and support healing may, under certain conditions, be toxic to the primary regenerative cells in the target tissue. A potential explanation for this dual effect may lie in its composition. PEA is an amide of palmitic acid (palmitate). A separate *in vitro* study demonstrated that palmitate itself induces inflammation, endoplasmic reticulum (ER) stress, and apoptosis (programmed cell death) in tenocytes.<sup>54</sup> It is biologically plausible that at lower, therapeutic concentrations, PEA's beneficial signaling effects via PPAR- $\alpha$  and mast cell modulation predominate. However, at higher concentrations, these benefits may be overwhelmed by the intrinsic cytotoxicity of its palmitate component. This suggests that for PEA, dosage may be a critical determinant of whether the net effect on tendon tissue is beneficial or detrimental, and that "more is not necessarily better."

## **Part IV: The Frontier of Tendon Regeneration: Neurotrophics and Peptides**

This section explores more experimental and cutting-edge therapeutic strategies for tendon repair, moving from the scientifically grounded concept of the neuro-tendon axis to the highly promising yet speculative world of bioactive peptides.

### **Section 4.1: The Neuro-Tendon Axis: The Emerging Role of Neurotrophic Factors in**

## Healing

A new paradigm is emerging in tendon biology that repositions the nervous system from a passive conduit for pain signals to an active and essential regulator of tendon homeostasis, inflammation, and repair.<sup>55</sup> Following a tendon injury, there is an ingrowth of nerve fibers into the tendon proper. These nerves release a variety of neuromediators, including neurotrophic factors such as Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), which appear to play a critical role in orchestrating the healing process.<sup>55</sup>

The mechanisms of these neurotrophins are multifaceted. Animal models of ligament injury have shown that the local administration of NGF can promote angiogenesis (the formation of new blood vessels) and ultimately lead to improvements in the biomechanical strength of the healed tissue.<sup>55</sup> Conversely, levels of BDNF appear to be important for maintaining tendon health, as its expression is downregulated by disuse following injury, which may contribute to tissue atrophy.<sup>55</sup> The importance of this neuro-tendon axis is further highlighted in models of metabolic disease. In diabetic rats, which exhibit impaired tendon healing, the repair process is associated with a significant downregulation of NGF and BDNF signaling pathways. This suggests that therapeutic modulation of these neurotrophic factors could represent a novel strategy to enhance tendon regeneration, particularly in compromised patient populations.<sup>56</sup> More recent research in ovine models has shown that the expression levels of neural markers like NGF, CGRP, and GAL can predict the quality of tendon healing, correlating with better collagen organization and maturation.<sup>58</sup> Other growth factors, such as Fibroblast Growth Factor-2 (FGF-2), have also shown promise in animal models, improving fibril organization, increasing vascularity, and reducing inflammation in healing Achilles tendons.<sup>59</sup>

### Section 4.2: Bioactive Peptides: A High-Potential, High-Risk Arena

The use of peptides for tissue repair has gained immense popularity, but it is a field characterized by a sharp divide between scientifically validated supplements and highly speculative, unregulated compounds. It is critical to differentiate between these categories.

### **Subsection 4.2.1: Specific Collagen Peptides: Clinically Validated Support for Tendon Matrix Repair**

Specific collagen peptides fall into the "building block" category of supplements. They are small chains of amino acids derived from the enzymatic hydrolysis of collagen. The therapeutic rationale is that oral supplementation provides a concentrated source of the key amino acids required for tendon ECM synthesis—notably glycine, proline, and hydroxyproline—making these substrates readily available to tenocytes for the production of new collagen.<sup>31</sup> In vitro studies have confirmed that specific collagen peptides can stimulate fibroblasts to synthesize ECM molecules like collagen type I.<sup>43</sup>

Crucially, this approach is supported by direct human clinical evidence. A 2019 pilot, double-blind, randomized controlled trial investigated the effects of a specific collagen peptide product (TENDOFORTE®) in patients with chronic mid-portion Achilles tendinopathy.<sup>42</sup> Participants took 5 grams of the peptide supplement daily in conjunction with a structured calf-strengthening program. The results showed that the group receiving the collagen peptides experienced a significantly faster and greater improvement in both pain and function (as measured by the VISA-A score) compared to the group performing the same exercises with a placebo.<sup>40</sup> Importantly, no adverse events were reported. Other clinical studies have shown that similar supplementation can increase the cross-sectional area and improve the mechanical properties of the patellar tendon in individuals undergoing resistance training.<sup>43</sup> This body of evidence positions specific collagen peptides as a low-risk, evidence-based supportive therapy for tendinopathy.

### **Subsection 4.2.2: BPC-157: A Case Study in Hype Versus Evidence**

In stark contrast to collagen peptides, Body Protection Compound-157 (BPC-157) is a synthetic "signaling" peptide that exists in a high-risk, high-reward arena characterized by a chasm between preclinical promise and a lack of human data. BPC-157 is a 15-amino-acid sequence originally derived from a protein found in human gastric juice.<sup>62</sup>

Preclinical research, conducted almost exclusively in animal models (mostly rodents),

is impressive. These studies suggest that BPC-157 accelerates the healing of a wide range of tissues, including tendons, by activating the focal adhesion kinase (FAK)-paxillin signaling pathway in tendon fibroblasts. This activation promotes the migration and survival of these repair cells at the injury site.<sup>64</sup> It has also been shown to upregulate growth hormone receptors on tenocytes and promote angiogenesis.<sup>63</sup>

However, there is a profound lack of human evidence. There are no rigorous, published, randomized, placebo-controlled clinical trials of BPC-157 for tendon repair or any other condition in humans.<sup>62</sup> The "human evidence" that is often cited consists of a few very small, unblinded, uncontrolled case series, often conducted by clinics with a clear financial conflict of interest, making the results unreliable.<sup>62</sup> This lack of data has led to its status as an unapproved substance by the U.S. Food and Drug Administration (FDA) for any clinical use and its inclusion on the World Anti-Doping Agency (WADA) Prohibited List.<sup>62</sup>

Despite this, BPC-157 is widely promoted online and has a strong following, fueled by powerful anecdotal reports of rapid and dramatic recovery from chronic injuries, including tendonitis and herniated discs, from both high-profile individuals and anonymous forum users.<sup>69</sup>

The disconnect between preclinical promise and the lack of human data is concerning, but the most significant issue lies in the biological plausibility of its potential for harm. The very mechanisms that make BPC-157 a potentially potent healing agent—the robust activation of cell migration and the stimulation of angiogenesis—are the same fundamental pathways that are hijacked by cancer cells to facilitate tumor growth, invasion, and metastasis.<sup>65</sup> FAK signaling and angiogenesis (via receptors like VEGFR2, which BPC-157 upregulates) are well-established drivers of cancer progression. Therefore, introducing a powerful, systemic activator of these pathways could theoretically promote the growth or spread of a pre-existing, undiagnosed malignancy. While no study has proven that BPC-157 causes cancer in humans, this risk is biologically sound and, in the absence of long-term human safety data, completely unquantified.

**Table 4: Risk-Benefit Analysis of Investigational Peptides for Tendon Repair**

Feature	Specific Collagen Peptides	BPC-157 (Body Protection Compound-157)
Mechanism Category	Building Block	Signaling



<b>Proposed Action</b>	Provides amino acid substrates for ECM synthesis.	Activates cell migration (FAK-paxillin) and angiogenesis.
<b>Human Clinical Evidence</b>	Positive pilot RCTs showing accelerated recovery in Achilles tendinopathy.	None. Limited to small, uncontrolled, biased case series.
<b>Regulatory Status</b>	Generally Recognized as Safe (GRAS) as a food ingredient.	Not approved by FDA. Banned by WADA.
<b>Primary Benefit</b>	Moderate acceleration of clinical recovery when combined with exercise.	Potentially rapid and dramatic healing (anecdotal).
<b>Key Safety Concern</b>	Low risk; well-tolerated in clinical trials.	Unknown long-term safety. Biologically plausible risk of promoting cancer growth and metastasis.

## Part V: Synthesis, Recommendations, and Future Outlook

This integrative analysis has traversed the landscape from a specific drug-induced tendinopathy to the broader frontiers of tendon repair. The synthesis of clinical, preclinical, and anecdotal evidence yields several key conclusions and provides a basis for risk-stratified recommendations for the proactive health investigator.

### Synthesis of Findings

- 1. The Risk of Bempedoic Acid-Induced Tendinopathy is Real but Small:** The initial safety signal from early trials (0.5% vs. 0% rupture rate) has been significantly diluted by the large-scale CLEAR Outcomes trial, which showed only a small, non-significant numerical difference in rupture rates (1.2% vs. 0.9%) and an identical rate of overall tendon-related issues (2.0% in both groups). The true attributable risk appears to be very low and likely concentrated in patients with pre-existing risk factors.
- 2. A Causal Mechanism Remains Unknown:** A critical knowledge gap persists

regarding how bempedoic acid could biologically induce tendon damage. The presence or absence of its activating enzyme, ACSVL1, in human tenocytes has not been studied, leaving its potential for direct local action an open question.

3. **No Specific Treatment Exists:** There are no targeted therapies for reversing or treating bempedoic acid-induced tendon injury. Management relies on the general principles of discontinuing the offending agent and implementing a structured rehabilitation program.
4. **Nutraceuticals Show Modest, Mechanistically Diverse Promise:** Natural compounds for tendon support can be categorized by their proposed mechanism ("building blocks" like collagen vs. "signaling modulators" like curcumin). The evidence for most is primarily preclinical, though some, like curcumin, show promise for pain relief in small human studies.
5. **The PEA Paradox:** Palmitoylethanolamide (PEA) is well-supported by clinical data as a safe and effective analgesic. However, *in vitro* data revealing potential cytotoxicity to tendon stem cells at high concentrations introduces a crucial note of caution, suggesting that dose is a critical determinant of its net effect on tendon tissue.
6. **A Sharp Divide in the Peptide Landscape:** The world of peptides for tendon repair is bifurcated. Specific collagen peptides are a low-risk, evidence-based "building block" therapy with positive human trial data for tendinopathy. In contrast, BPC-157 is a high-risk, experimental "signaling" agent with no rigorous human data, a plausible but unquantified cancer risk, and a reputation built on animal studies and anecdotes.

## Risk-Stratified Recommendations

- **Regarding Bempedoic Acid Use:** The decision to initiate or continue bempedoic acid therapy should involve a shared decision-making process that explicitly weighs the significant, proven cardiovascular benefits against the very low absolute risk of tendon injury. This conversation is particularly important for patients with multiple pre-existing risk factors for tendinopathy (age >60, renal impairment, corticosteroid/fluoroquinolone use, prior tendon issues). For these individuals, the risk-benefit calculation may shift, and heightened vigilance for tendon-related symptoms is warranted.
- **For Evidence-Based Tendon Support:** For individuals seeking to support tendon health and recovery from injury, the most scientifically grounded approach is to combine a structured, progressive exercise program with oral supplementation of

specific, hydrolyzed collagen peptides (e.g., 5-10 g/day). The addition of a high-quality, bioavailable curcumin supplement may provide further anti-inflammatory and analgesic benefits. PEA may be considered for pain management, but with the understanding of the potential dose-dependent cytotoxicity, suggesting that conservative dosing is prudent.

- **Regarding Experimental Therapies:** The use of BPC-157 should be recognized as a high-risk, experimental intervention that falls outside the bounds of conventional, evidence-based medicine. The decision to use such a compound represents a significant gamble, trading unproven benefits (based on anecdotes) for plausible and entirely unquantified long-term safety risks, most notably the theoretical potential for cancer potentiation.

## Future Outlook and Research Gaps

To resolve the uncertainties highlighted in this report, several key areas of research must be prioritized:

1. **Elucidating the Bempedoic Acid Mechanism:** Foundational *in vitro* research is urgently needed to determine if the activating enzyme ACSVL1 is expressed in human tenocytes and tendon sheath cells. This single study would clarify whether a direct pharmacological effect of bempedoic acid on tendon tissue is biologically plausible.
2. **Defining the PEA Therapeutic Window:** Dose-response studies are required to investigate the "PEA paradox." These studies should aim to identify the concentration range at which PEA provides maximal anti-inflammatory and analgesic benefits without inducing cytotoxicity in tendon-derived stem cells.
3. **Establishing the True Profile of BPC-157:** The widespread, unregulated use of BPC-157 necessitates the urgent initiation of rigorous, independent, long-term, placebo-controlled human clinical trials. Such trials are essential to definitively establish not only its efficacy for tendon and other tissue repair but, most critically, its long-term safety profile, with a specific focus on oncological outcomes.

Until these research gaps are filled, patients and clinicians must continue to navigate this complex landscape with a critical eye, prioritizing interventions with demonstrated human safety and efficacy while approaching speculative therapies with the profound

caution they warrant.

## Works cited

1. Addition of Bempedoic Acid to Statin–Ezetimibe versus Statin Titration in Patients with High Cardiovascular Risk: A Single-Centre Prospective Study - MDPI, accessed June 15, 2025, <https://www.mdpi.com/2308-3425/11/9/286>
2. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome - Frontiers, accessed June 15, 2025, <https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1028355/full>
3. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9650075/>
4. Efficacy and Safety of Bempedoic Acid in Patients with Hyperlipidemia and Non-Alcoholic Fatty Liver Disease - GBMC Healthcare Scholarly Commons, accessed June 15, 2025, <https://scholarlycommons.gbmc.org/cgi/viewcontent.cgi?article=1313&context=jchimp>
5. Role of Bempedoic Acid in Clinical Practice - PMC, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8266788/>
6. Efficacy and Safety Data for Bempedoic Acid - HCPLive, accessed June 15, 2025, <https://www.hcplive.com/view/efficacy-and-safety-data-for-bempedoic-acid>
7. Bempedoic Acid (Nexletol) for the Treatment of Hyperlipidemia and Familial Hypercholesterolemia | AAFP, accessed June 15, 2025, <https://www.aafp.org/pubs/afp/issues/2021/0315/p377.html>
8. Landmark CLEAR Outcomes Study Demonstrates NEXLETOL ..., accessed June 15, 2025, <https://www.dicardiology.com/content/landmark-clear-outcomes-study-demonstrates-nexletol-bempedoic-acid-tablet-only-ldl-c>
9. Bempedoic acid: what prospective uses? - PMC, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10132602/>
10. Homo sapiens - WikiPathways, accessed June 15, 2025, <https://www.wikipathways.org/search.html?query=SMS&species=Homo+sapiens&title=Special%3ASearchPathways&doSearch=1&ids=&codes=&type=query>
11. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia | Request PDF - ResearchGate, accessed June 15, 2025, [https://www.researchgate.net/publication/352907472\\_Evaluating\\_pharmacokinetics\\_of\\_bempedoic\\_acid\\_in\\_the\\_treatment\\_of\\_hypercholesterolemia](https://www.researchgate.net/publication/352907472_Evaluating_pharmacokinetics_of_bempedoic_acid_in_the_treatment_of_hypercholesterolemia)
12. Bempedoic Acid: A New Tool for LDL-Cholesterol Control in Patients with Coronary Artery Disease - PMC, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11273861/>
13. Bempedoic acid: what prospective uses? | European Heart Journal Supplements, accessed June 15, 2025, [https://academic.oup.com/eurheartjsupp/article/25/Supplement\\_C/C109/7143254](https://academic.oup.com/eurheartjsupp/article/25/Supplement_C/C109/7143254)

14. Safety of Bempedoic Acid in Patients at High Cardiovascular Risk and with Statin Intolerance - ResearchGate, accessed June 15, 2025, [https://www.researchgate.net/publication/375122464\\_Safety\\_of\\_Bempedoic\\_Acid\\_in\\_Patients\\_at\\_High\\_Cardiovascular\\_Risk\\_and\\_with\\_Statin\\_Intolerance](https://www.researchgate.net/publication/375122464_Safety_of_Bempedoic_Acid_in_Patients_at_High_Cardiovascular_Risk_and_with_Statin_Intolerance)
15. Bempedoic Acid - StatPearls - NCBI Bookshelf, accessed June 15, 2025, <https://www.ncbi.nlm.nih.gov/books/NBK594232/>
16. CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology, accessed June 15, 2025, <https://www.dicardiology.com/content/clear-outcomes-accepted-late-breaking-clinical-trial-acc23-annual-scientific-session-expo>
17. BEMPEDOIC ACID (ETC-1002) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002 - ClinicalTrials.gov, accessed June 15, 2025, [https://cdn.clinicaltrials.gov/large-docs/06/NCT02993406/Prot\\_000.pdf](https://cdn.clinicaltrials.gov/large-docs/06/NCT02993406/Prot_000.pdf)
18. Adverse Event Profile of Bempedoic Acid - Managed Healthcare Executive, accessed June 15, 2025, <https://www.managedhealthcareexecutive.com/view/adverse-event-profile-of-bempedoic-acid>
19. Study Shows Bempedoic Acid Comparable to Statins in Cardiovascular Protection, accessed June 15, 2025, <https://www.hcplive.com/view/study-shows-bempedoic-acid-comparable-to-statins-in-cardiovascular-protection>
20. Fluoroquinolones and Tendinopathy: A Guide for Athletes and ..., accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4080593/>
21. Fluoroquinolone-Mediated Tendinopathy and Tendon Rupture - MDPI, accessed June 15, 2025, <https://www.mdpi.com/1424-8247/18/2/184>
22. Fluoroquinolone-induced Achilles tendinitis - HKMJ |, accessed June 15, 2025, <https://www.hkmj.org/abstracts/v20n6/545.htm>
23. Fluoroquinolone-Induced Tendinopathy: Etiology and Preventive Measures - J-Stage, accessed June 15, 2025, [https://www.jstage.jst.go.jp/article/tjem/226/4/226\\_4\\_251/article](https://www.jstage.jst.go.jp/article/tjem/226/4/226_4_251/article)
24. The Risk of Fluoroquinolone-induced Tendinopathy and Tendon Rupture: What Does The Clinician Need To Know?, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC2921747/>
25. Is Statin Use Associated With Tendon Rupture? A Population-Based Retrospective Cohort Analysis | Request PDF - ResearchGate, accessed June 15, 2025, [https://www.researchgate.net/publication/259875975\\_Is\\_Statin\\_Use\\_Associated\\_With\\_Tendon\\_Rupture\\_A\\_Population-Based\\_Retrospective\\_Cohort\\_Analysis](https://www.researchgate.net/publication/259875975_Is_Statin_Use_Associated_With_Tendon_Rupture_A_Population-Based_Retrospective_Cohort_Analysis)
26. Drug-induced tendinopathy - Medsafe, accessed June 15, 2025, <https://www.medsafe.govt.nz/profs/PUArticles/September2024/Drug-induced-tendinopathy.html>
27. When to Call, When to Counsel: Fluoroquinolone Tendinopathy - Pharmacy Times, accessed June 15, 2025, <https://www.pharmacytimes.com/view/when-to-call-when-to-counsel-fluoroquinolone-tendinopathy>

[olone-tendinopathy](#)

28. Tendinopathy - Diagnosis and treatment - Mayo Clinic, accessed June 15, 2025, <https://www.mayoclinic.org/diseases-conditions/tendinopathy/diagnosis-treatment/drc-20580691>
29. Treatment of Tendinopathy: What Works, What Does Not, and What is on the Horizon - PMC, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC2505250/>
30. Physical Therapist Management of Fluoroquinolone-Induced Achilles Tendinopathy - Oxford Academic, accessed June 15, 2025, <https://academic.oup.com/ptj/article/82/12/1224/2857752>
31. Nutraceutical supplement in the management of tendinopathies: a systematic review - PMC, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC4915461/>
32. Does Additional Dietary Supplementation Improve Physiotherapeutic Treatment Outcome in Tendinopathy? A Systematic Review and Meta-Analysis - PubMed, accessed June 15, 2025, <https://pubmed.ncbi.nlm.nih.gov/35329992/>
33. Is Curcumine Useful in the Treatment and Prevention of the Tendinopathy and Myotendinous Junction Injury? A Scoping Review - PubMed Central, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9860696/>
34. Modulation of Inflammation by Plant-Derived Nutraceuticals in Tendinitis - PMC, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9143056/>
35. Palmitoylethanolamide: A Natural Compound for Health ..., accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8157570/>
36. Curcumin Improves Functional Recovery of Ruptured Tendon by Promoting Tenogenesis via PI3K/Akt Signaling | Stem Cells Translational Medicine | Oxford Academic, accessed June 15, 2025, <https://academic.oup.com/stcltm/article/13/5/477/7612774>
37. Effects of curcumin on IL-1 -induced inhibition of extracellular... - ResearchGate, accessed June 15, 2025, [https://www.researchgate.net/figure/Effects-of-curcumin-on-IL-1-induced-inhibition-of-extracellular-matrix-compounds-and\\_fig2\\_51216055](https://www.researchgate.net/figure/Effects-of-curcumin-on-IL-1-induced-inhibition-of-extracellular-matrix-compounds-and_fig2_51216055)
38. Influence of Supplements and Drugs used for the Treatment of ..., accessed June 15, 2025, <https://www.mltj.online/wp-content/uploads/2020/10/376-284.pdf>
39. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials - PubMed Central, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10053226/>
40. Oral Supplementation of Specific Collagen Peptides Combined with Calf-Strengthening Exercises Enhances Function and Reduces Pain in Achilles Tendinopathy Patients - MDPI, accessed June 15, 2025, <https://www.mdpi.com/2072-6643/11/1/76>
41. Oral Supplementation of Specific Collagen Peptides Combined with Calf-Strengthening Exercises Enhances Function and Reduces Pain in Achilles Tendinopathy Patients - PubMed, accessed June 15, 2025, <https://pubmed.ncbi.nlm.nih.gov/30609761/>
42. Oral Supplementation of Specific Collagen Peptides Combined with ..., accessed



- June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC6356409/>
43. Full article: Specific collagen peptides increase adaptations of patellar tendon morphology following 14-weeks of high-load resistance training: A randomized-controlled trial - Taylor & Francis Online: Peer-reviewed Journals, accessed June 15, 2025, <https://www.tandfonline.com/doi/full/10.1080/17461391.2023.2232758>
  44. Turmeric Probably Won't Help Your Arthritis, But Curcumin Might, accessed June 15, 2025, <https://www.arthritis.org/health-wellness/healthy-living/nutrition/anti-inflammatory/turmeric-wont-help-arthritis>
  45. Customer reviews for Turmeric Curcumin with Bioperine Black ..., accessed June 15, 2025, <https://www.walmart.com/reviews/product/901174615>
  46. Terry Naturally CuraMed Acute Pain Relief - Supplement with BCM-95 Curcumin & BOS-10 Boswellia - Black Sesame Seed Oil to Support Relief of Occasional Discomfort - 60 Liquid Gels - Amazon.com, accessed June 15, 2025, <https://www.amazon.com/Terry-Naturally-CuraMed-Relief-Liquid/dp/B08L412KFJ>
  47. Oral Supplementation with Ultramicronized Palmitoylethanolamide for Joint Disease and Lameness Management in Four Jumping Horses: A Case Report - MDPI, accessed June 15, 2025, <https://www.mdpi.com/2076-2615/10/9/1469>
  48. BPC+PEA 500 - Turnpaugh-health, accessed June 15, 2025, <https://shop.turnpaughhwc.com/products/bpc-pea-500>
  49. The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers—A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9570726/>
  50. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis | Request PDF - ResearchGate, accessed June 15, 2025, [https://www.researchgate.net/publication/332092649\\_A\\_double-blind\\_randomized\\_placebo\\_controlled\\_study\\_assessing\\_safety\\_tolerability\\_and\\_efficacy\\_of\\_palmitoylethanolamide\\_for\\_symptoms\\_of\\_knee\\_osteoarthritis](https://www.researchgate.net/publication/332092649_A_double-blind_randomized_placebo_controlled_study_assessing_safety_tolerability_and_efficacy_of_palmitoylethanolamide_for_symptoms_of_knee_osteoarthritis)
  51. Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis - MDPI, accessed June 15, 2025, <https://www.mdpi.com/2072-6643/16/11/1653>
  52. (PDF) Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials - ResearchGate, accessed June 15, 2025, [https://www.researchgate.net/publication/369159003\\_Palmitoylethanolamide\\_in\\_the\\_Treatment\\_of\\_Chronic\\_Pain\\_A\\_Systematic\\_Review\\_and\\_Meta-Analysis\\_of\\_Double-Blind\\_Randomized\\_Controlled\\_Trials](https://www.researchgate.net/publication/369159003_Palmitoylethanolamide_in_the_Treatment_of_Chronic_Pain_A_Systematic_Review_and_Meta-Analysis_of_Double-Blind_Randomized_Controlled_Trials)
  53. Palmitoylethanolamide (PEA): Anyone had success? - Mayo Clinic Connect, accessed June 15, 2025, <https://connect.mayoclinic.org/discussion/pea-success/>
  54. Developmental endothelial locus-1 attenuates palmitate-induced ..., accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC9792873/>
  55. Neuronal regulation of tendon homeostasis - PMC, accessed June 15, 2025,

- <https://pmc.ncbi.nlm.nih.gov/articles/PMC3721458/>
56. Compromised Neurotrophic and Angiogenic Regenerative Capability during Tendon Healing in a Rat Model of Type-II Diabetes | PLOS One, accessed June 15, 2025, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170748>
  57. Compromised Neurotrophic and Angiogenic Regenerative Capability during Tendon Healing in a Rat Model of Type-II Diabetes - Semantic Scholar, accessed June 15, 2025, <https://pdfs.semanticscholar.org/365b/7588894ad2c19cef6628a3b9e0a353f2a8f6.pdf>
  58. Neural Markers Predict Tendon Healing Outcomes in an Ovine Achilles Tendon Injury Model: Spontaneous Repair Versus Amniotic Epithelial Cell-Induced Regeneration - PubMed Central, accessed June 15, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11942428/>
  59. FGF-2 enriched nanofiber scaffold for advancing achilles tendon healing: a comparative experimental investigation - Frontiers, accessed June 15, 2025, <https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2024.1424734/full>
  60. The Effect of Collagen Hydrolysate Ingestion in Tendinopathy: - ClinicalTrials.gov, accessed June 15, 2025, [https://cdn.clinicaltrials.gov/large-docs/18/NCT04578418/SAP\\_000.pdf](https://cdn.clinicaltrials.gov/large-docs/18/NCT04578418/SAP_000.pdf)
  61. (PDF) Oral Supplementation of Specific Collagen Peptides Combined with Calf-Strengthening Exercises Enhances Function and Reduces Pain in Achilles Tendinopathy Patients - ResearchGate, accessed June 15, 2025, [https://www.researchgate.net/publication/330108406\\_Oral\\_Supplementation\\_of\\_Specific\\_Collagen\\_Peptides\\_Combined\\_with\\_Calf-Strengthening\\_Exercises\\_Enhances\\_Function\\_and\\_Reduces\\_Pain\\_in\\_Achilles\\_Tendinopathy\\_Patients](https://www.researchgate.net/publication/330108406_Oral_Supplementation_of_Specific_Collagen_Peptides_Combined_with_Calf-Strengthening_Exercises_Enhances_Function_and_Reduces_Pain_in_Achilles_Tendinopathy_Patients)
  62. BPC-157 for athletes: Science, safety, and legal concerns - Sports Injury Physio, accessed June 15, 2025, <https://www.sports-injury-physio.com/post/the-peptide-bpc-157-good-for-athletes>
  63. BPC 157: Science-Backed Uses, Benefits, Dosage, and Safety - Rupa Health, accessed June 15, 2025, <https://www.rupahealth.com/post/bpc-157-science-backed-uses-benefits-dosage-and-safety>
  64. Peptide Therapies - Alpine Spine & Orthopedics Institute, accessed June 15, 2025, <https://www.alpinespineorthopedics.com/peptides>
  65. BPC-157: Miracle Healing Peptide or Hidden Danger? - Prisk Orthopaedics and Wellness, accessed June 15, 2025, <https://www.orthoandwellness.com/blog/bpc-157-update-and-deep-dive-miracle-healing-peptide-or-hidden-danger?source=googleads>
  66. BPC 157: is this a supplement I should be taking to improve my healing?, accessed June 15, 2025, <https://www.posmc.com/bpc-157-is-this-a-supplement-i-should-be-taking-to-improve-my-healing/>
  67. The Dangers of Using BPC-157 as a “Prescribed” Peptide for Musculoskeletal



Injuries, accessed June 15, 2025,

<https://www.orthoandwellness.com/blog/the-dangers-of-using-bpc-157-as-a-prescribed-peptide-for-musculoskeletal-injuries>

68. BPC 157 Banned: Key Facts on the Latest FDA Decision - Optimize Performance Medicine, accessed June 15, 2025,

<https://optimizemyhealth.com/bpc-157-banned-the-latest-fda-decision/>

69. What Science ACTUALLY Says About BPC 157 Benefits - YouTube, accessed June 15, 2025, <https://www.youtube.com/watch?v=gaQwrB8HW4o>

70. What is BPC 157 - The Peptide Huberman and Rogan Can't Stop Talking About, accessed June 15, 2025, <https://www.thepiazzacenter.com/blog/what-is-bpc-157/>